For years, the pathway from a medical breakthrough in the lab to a bedside application in the clinic has been hindered by a growing regulatory bottleneck in Europe. The transition to the European Union’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) was designed to increase safety and transparency, but in practice, it created a daunting backlog that threatened to stall innovation and limit patient access to cutting-edge technology.
The Spanish Agency for Medicines and Health Products (AEMPS) has now signaled its support for a European Commission proposal aimed at solving this crisis: the implementation of maximum deadlines for the evaluation of medical devices and in vitro diagnostic (IVD) products. By capping the time regulators and Notified Bodies can take to review applications, the EU aims to replace current uncertainty with a predictable timeline, ensuring that life-saving tools do not languish in administrative limbo.
As a physician, I have seen how these delays manifest in real-world clinical settings. When a new diagnostic kit for early cancer detection or a specialized cardiac stent is delayed by eighteen months due to a paperwork backlog, it isn’t just a corporate inconvenience—it is a gap in patient care. The AEMPS’s endorsement of these deadlines reflects a growing consensus that rigorous safety standards must be balanced with timely market access.
Solving the Notified Body Bottleneck
At the heart of the issue is the role of Notified Bodies (NBs)—the third-party organizations designated by EU member states to assess the conformity of certain products before they are placed on the market. Under the previous directives, the process was more flexible, but the move to the MDR (EU 2017/745) and IVDR (EU 2017/746) significantly raised the bar for clinical evidence and technical documentation.
While the higher standards are a victory for patient safety, the number of qualified Notified Bodies did not grow proportionally to the increased workload. This created a systemic “pinch point.” Manufacturers found themselves in a queue with no clear end date, making it nearly impossible to plan research and development cycles or secure investment for new medical technologies.
The proposed regulation addresses this by establishing hard ceilings on evaluation periods. By modifying Annex VII of both the MDR and IVDR, the Commission intends to streamline the technical documentation requirements and force a more disciplined cadence of review. The AEMPS views this not as a shortcut that compromises safety, but as a necessary administrative correction to ensure the regulations are functional rather than obstructive.
Who Stands to Gain?
The impact of these deadlines ripples across the entire healthcare ecosystem, affecting three primary stakeholder groups:
- Patients: The most direct beneficiaries. Shorter evaluation windows mean faster access to next-generation diagnostics and therapeutic devices, reducing the “innovation gap” between the US and EU markets.
- Manufacturers: Small and medium-sized enterprises (SMEs) are particularly vulnerable to long delays. Predictable timelines allow these companies to manage cash flow and allocate resources more effectively.
- Healthcare Providers: Surgeons and clinicians gain access to updated tools that can improve surgical outcomes or diagnostic accuracy without waiting years for regulatory clearance.
The Technical Shift: Modifying Annex VII
The regulatory adjustment focuses heavily on Annex VII, which dictates the technical documentation a manufacturer must provide to prove a device’s safety, and performance. The goal is to refine what is “essential” versus what is “supplementary,” reducing the volume of redundant data that Notified Bodies must sift through.
By clarifying these requirements, the EU hopes to reduce the number of “requests for additional information” (RAIs). Currently, a common cycle involves a Notified Body requesting more data, the manufacturer providing it, and the clock effectively resetting. The new framework seeks to limit these iterations, pushing for a more comprehensive initial submission and a more decisive review process.
| Feature | Previous/Current Framework | Proposed Framework |
|---|---|---|
| Review Timelines | Variable/Unpredictable | Strict Maximum Deadlines |
| Documentation | Broad Annex VII Requirements | Streamlined/Modified Annex VII |
| Market Entry | Prone to administrative delays | Predictable, time-bound access |
| NB Capacity | Overwhelmed by backlog | Forced efficiency via deadlines |
Remaining Constraints and Unknowns
Despite the optimism from the AEMPS, significant questions remain regarding the capacity of Notified Bodies to actually meet these deadlines. A deadline on paper does not automatically create more qualified auditors. There is a risk that if NBs are rushed, the quality of the review could suffer, or conversely, that NBs may become even more selective about which applications they accept to ensure they can meet the legal time limits.
the industry is still navigating the “grace periods” extended by the EU to prevent thousands of legacy devices from disappearing from the market overnight. The coordination between these temporary extensions and the new maximum evaluation deadlines will be critical to avoid a secondary wave of market shortages.
Official updates regarding the final adoption of these deadlines and the specific day-counts for different device classes can be tracked via the European Commission’s Medical Devices portal.
Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. For specific compliance requirements regarding EU 2017/745 and EU 2017/746, consult a certified regulatory affairs professional.
The next critical milestone will be the formal publication of the delegated act in the Official Journal of the European Union, which will trigger the countdown for the new deadlines to become legally binding. Once enacted, the industry will be watching closely to see if Notified Bodies can scale their operations to meet these mandates without compromising the rigorous safety standards the MDR was designed to uphold.
Do you think stricter deadlines will accelerate innovation or risk safety? Share your thoughts in the comments or share this story with your professional network.
